Related Experiment Video
Updated: Jul 6, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Vinflunine: clinical perspectives of an emerging anticancer agent
Adrian Yun-San Yip1, Eleanor Yuen-Yuen Ong, Louis Wing-Cheong Chow
1Comprehensive Centre for Breast Diseases, UNIMED Medical Institute, 10/F, Luk Kwok Centre, 72 Gloucester Road, Wanchai, Hong Kong.
Background:
Vinflunine is a novel second generation of Vinca alkaloid. The binding of vinflunine to tubulin and subsequent cellular arrest in mitosis is the core mechanism of this antineoplastic agent. In addition, its potential vascular-disrupting and antiangiogenic activities uphold further clinical development of this compound.
Objective:
To review and summarise the pharmacological and latest clinical data, and discuss the impact of vinflunine on current treatment regimens.
Methods:
A review of published literature and conference abstracts for results of previous preclinical and latest clinical studies in all cancer types was performed.
Results/Conclusions:
Noteworthy results from Phase II studies for treatment of non-small cell lung cancer (NSCLC), breast cancer and bladder cancer supported Phase III studies. One of the Phase III studies for treatment of advanced NSCLC showed important results. Encouraging results of combination use of vinflunine and other biologic agents also opened areas to investigate its synergistic or auxiliary role to existing therapies.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Treatment Resistent Cancers
Treatment Resistant Cancers
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...